Immune Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Desferrioxamine Chelation Treatment

Publisher： Karger

E-ISSN： 1421-9662|110|4|224-226

ISSN： 0001-5792

Source： Acta Haematologica, Vol.110, Iss.4, 2003-12, pp. : 224-226

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Combined Chelation Therapy with Daily Oral Deferiprone and Twice-Weekly Subcutaneous Infusion of Desferrioxamine in Children with β-Thalassemia: 3-Year Experience

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-11 ,pp. : 226-236

Karger

Access to resources Recommend Favorite

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine

By  

Acta Haematologica, Vol. 101, Iss. 4, 1999-07 ,pp. : 173-177

Karger

Access to resources Recommend Favorite

Five-Year Trial of Deferiprone Chelation Therapy in Thalassaemia major Patients

By  

Acta Haematologica, Vol. 112, Iss. 4, 2004-11 ,pp. : 179-183

Karger

Access to resources Recommend Favorite

Deferiprone Chelation Therapy for Thalassemia Major

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 155-164

Karger

Access to resources Recommend Favorite